Related Experiment Video
Updated: Aug 12, 2026
13:47
Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
Published on: June 23, 2011
Lithium ameliorates HIV-gp120-mediated neurotoxicity
Ian P Everall1, Christopher Bell, Margaret Mallory
1Section of Experimental Neuropathology and Psychiatry, Institute of Psychiatry, London, United Kingdom.
Molecular and Cellular Neurosciences
|December 25, 2002
Summary
Lithium pretreatment protected mice brains and neuronal cells from HIV gp120 toxicity. Prophylactic lithium may prevent HIV-associated cognitive impairments by offering neuroprotection.
Area of Science:
- Neuroscience
- Pharmacology
- Virology
Background:
- HIV-associated neurotoxicity is a significant clinical challenge.
- The HIV-1 glycoprotein 120 (gp120) is implicated in neuronal damage.
- Effective neuroprotective strategies are urgently needed.
Purpose of the Study:
- To evaluate the neuroprotective potential of lithium against HIV-gp120 toxicity.
- To investigate the efficacy of lithium as a prophylactic agent.
Main Methods:
- In vivo studies: Mice exposed to lithium and gp120; assessed neuronal and astrocyte markers.
- In vitro studies: SH-SY5Y neuronal cells exposed to gp120 and lithium; assessed cell viability.
- Pharmacological inhibition of the PI3K/Akt pathway.
Main Results:
- Lithium pretreatment significantly protected the mouse hippocampus from gp120-induced toxicity.
- Pre-exposure to lithium reduced neurotoxicity in neuronal cultures.
- Lithium posttreatment showed minimal neuroprotective effects.
- The neuroprotective effects of lithium in vitro were blocked by LY294002, an inhibitor of the PI3K/Akt pathway.
Conclusions:
- Lithium demonstrates neuroprotective properties against HIV-gp120 toxicity.
- Prophylactic administration of lithium may offer a strategy to prevent or slow HIV-associated cognitive impairments.
